Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBIT (2017 - 2025)

Autolus Therapeutics' EBIT history spans 6 years, with the latest figure at -$72.5 million for Q4 2025.

  • For Q4 2025, EBIT rose 4.48% year-over-year to -$72.5 million; the TTM value through Dec 2025 reached -$270.5 million, down 12.06%, while the annual FY2025 figure was -$270.5 million, 12.06% down from the prior year.
  • EBIT reached -$72.5 million in Q4 2025 per AUTL's latest filing, down from -$71.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.6 million in Q4 2022 to a low of -$75.9 million in Q4 2024.
  • Average EBIT over 4 years is -$51.0 million, with a median of -$48.8 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 357.26% in 2023, then rose 4.48% in 2025.
  • A 4-year view of EBIT shows it stood at -$11.6 million in 2022, then plummeted by 357.26% to -$53.3 million in 2023, then tumbled by 42.41% to -$75.9 million in 2024, then grew by 4.48% to -$72.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EBIT are -$72.5 million (Q4 2025), -$71.6 million (Q3 2025), and -$61.2 million (Q2 2025).